Volume 31, Number 1—January 2025
Research Letter
Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024
Alireza Abdolrasouli, Richard C. Barton, and Andrew M. Borman
Table
Characteristics of the 157 proven cases of in an investigation of spread of antifungal-resistant T. indotineae infection, United Kingdom, 2017–2024*
| Characteristics | No. (%), n = 157 |
|---|---|
| Patient age range, y | |
| 1–10 | 4 (2.5) |
| 11–20 | 13 (8.3) |
| 21–30 | 37 (23.6) |
| 31–40 | 42 (26.8) |
| 41–50 | 26 (16.6) |
| 51–60 | 18 (11.5) |
| 61–70 | 13 (8.3) |
| 71–80 |
4 (2.5) |
| Anatomic site affected† | |
| Buttock, groin, gluteal fold, perineum, thigh | 67 (42.7) |
| Back, abdomen, torso, trunk, breast, chest | 18 (11.5) |
| Legs, feet, knee, toenail | 14 (8.9) |
| Arms, hands, axilla | 6 (3.8) |
| Face, neck, head | 6 (3.8) |
| Unknown |
53 (33.8) |
| Geographic location | |
| London | 73 (46.5) |
| England outside London | 54 (34.4) |
| Wales | 8 (5.1) |
| Scotland | 19 (12.1) |
| Republic of Ireland |
3 (1.9) |
| Travel history‡ | |
| Yes | 41 (26.1) |
| No or unknown |
116 (73.9) |
| Patient links to endemic area | |
| Yes | 133 (84.7) |
| No | 12 (7.6) |
| Unknown |
12 (7.6) |
| Identification method | |
| Phenotypic only | 114 (72.6) |
| Molecular ITS or WGS |
43 (27.4) |
| Antifungal susceptibility testing | |
| Terbinafine, >0.5 mg/L | 92 (58.6) |
| Terbinafine, <0.5mg/L | 32 (20.4) |
| Terbinafine, not tested | 33 (21.0) |
| Itraconazole, >05 mg/L | 16 (10.2) |
| Itraconazole, <0.5 mg/L | 92 (58.6) |
| Itraconazole, not tested | 49 (31.2) |
*Detailed case listings and definitions are provided (Appendix Table, https://wwwnc.cdc.gov/EID/article/31/1/24-0923-App1.pdf). †Multiple sites reported in some cases; therefore, total >157 cases. ‡Travel to India, Bangladesh, Pakistan, Sri Lanka, UAE, Nepal.
Page created: November 20, 2024
Page updated: December 22, 2024
Page reviewed: December 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.